DTIL · Precision Biosciences Inc

Track DTIL — free

$6.30 +0.05 (+0.80%)

Russell 2000 member Rebalance outlook locked

Market Cap

$174.58M

27.60M

Volume · Oct 7 162.52K Avg daily vol (3M) 304.83K

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$45.05M

Trailing 12 months

Net income (TTM)

−$52.73M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-80.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-29.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+134.1%

Year over year · more shares

Price change (1Y)

+9.3%

Trailing year

Short interest

8.1%

Latest settlement · 10.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.1 · calm Equity put/call 0.63

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −1%

below

Price vs 50-day avg −13%

below

RSI (14) 37

neutral

MACD trend Positive

52-week position 47%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −14%

trailing

6-month return −17%

trailing

YTD return +50%

this year

Relative strength −28%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $7 › 200d $6 — 50d above 200d

Institutional flow Flat

1 of 96 funds reported for Sep 30 · net 0 sh shares

Insider flow Accumulating

Net +$29.5K over 90 days · 0% sells

Short interest Falling

8.06% of float · ▼ -11.7% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

96 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

EPS growth −442%

Y/Y

Balance sheet $167.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −59%

past year

ATR 5.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 7, 2025

Annual cash operating expenses reduction · each of 2026 and 2027 $25M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−1% Neutral

Price vs 50-day avg

−13% Bearish

RSI (14)

37 Neutral

MACD trend

Positive Bullish

52-week position

47% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $7 › 200d $6 — 50d above 200d

Institutional flow Flat

1 of 96 funds reported for Sep 30 · net 0 sh shares

Insider flow Accumulating

Net +$29.5K over 90 days · 0% sells

Short interest Falling

8.06% of float · ▼ -11.7% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

96 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $4 Now $6 · 47% Range high $9

vs 200-day avg -1% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DTIL Precision Biosciences Inc this stock	$174.58M	+50.2%	-50.1%	—	8.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.5%	+46.2%	30.7	1.9%
MRNA Moderna, Inc.	$78.44B	+566.3%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.40B	-3.9%	+20.8%	18.4	2.5%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders

Holders

% held: 64.1%
Reported: 1 of 96
Top holder: Aberdeen Group plc

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.2M

Days to cover: 10.6d
Change: -295.5K sh

View

Short Volume

Short vol %

65%

As of: Oct 7, 2026

Short Total

View

Fails to Deliver

FTD shares

5.8K

Value: $42.2K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

41.0%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Cluster buy

Net (90d)

+$29.5K

Buyers / Sellers: 3 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$34.3M

Net income (FY): $-45.7M
EPS diluted: $-3.56

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 24, 2026
This year: 18

View

Proposed Sales

Value

$18.9K

Shares: 4.9K
Filed: Feb 18, 2026

View

Earnings & Events

Webcasts

Last webcast

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
DTIL	-0.2%	-13.8%	-17.0%	-0.2%	+50.2%
SPY	+1.9%	+1.9%	+10.8%	+1.9%	+14.0%
vs SPY	-2.1%	-15.7%	-27.8%	-2.1%	+36.3%

Key facts CIK 1357874 CUSIP 74019P207 13F (30d) 2 filings 2 filers Visit website Investor relations

DTIL · Precision Biosciences Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance